Stock FNA PARAGON 28, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Paragon 28, Inc.

Equities

FNA

US69913P1057

Real-time Estimate Cboe BZX
Other stock markets
 19:44:55 02/05/2024 BST 		5-day change 1st Jan Change
9.915 USD +0.56% Intraday chart for Paragon 28, Inc. +9.75% -20.80%
04-04 Sector Update: Health Care Stocks Slump Late Afternoon MT
04-04 Sector Update: Health Care MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
PARAGON 28, INC. Stock Paragon 28, Inc.
-20.80% 817M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.77% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-2.04% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.47% 67.52B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.65% 50.06B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.08% 45.67B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.81% 26.73B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.00% 26.47B
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.23% 25.05B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FNA Stock
  4. Ratings Paragon 28, Inc.